Tranexamic acid for bleeding in the brain from a stroke
Tests tranexamic acid in adults with bleeding inside the brain from a stroke.
Plain-language title generated from the registry record
Registry title: Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
Key facts
- Where
- Bagno a Ripoli, Bari, Belluno, Bergamo, Cagliari, Carpi, Cremona, Florence, Frattamaggiore, L’Aquila, Lecco, Legnano, Mantova, Massa, Milan, Monserrato, Naples, Novara, Palermo, Perugia, Pisa, Rome, and Trieste, ItalySee the 26 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had a sudden bleed inside the brain (intracerebral haemorrhage) in the last 4.5 hours and are given tranexamic acid (TXA).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Spontaneous bleed in the brain, confirmed on a brain scan, within 4.5 hours of onset. If the start time is unknown, within 4.5 hours of when the symptoms were discovered.
- Earlier treatment
- People taking direct oral anticoagulants can join. People taking warfarin or low molecular weight heparin at the time of enrolment cannot join.
Main reasons for not taking part
- Known reason to be treated with TXA, for example traumatic brain injury
- Active seizures, or a current blood clot in a vein or artery
- Known allergy to TXA or normal saline
- Known problem in the brain's structure, such as aneurysm, tumor or arteriovenous malformation
- Very large bleed (more than 60ml), severe coma (Glasgow Coma Scale below 5), or end-of-life care already decided
Read by machine on 9 November 2026.
Where in Italy
- Ospedale Santa Maria AnnunziataBagno a Ripoli, ItalyTaking people
- University Of Bari Aldo MoroBari, ItalyTaking people
- IRCCS Ospedale Policlinico San MartinoBelluno, ItalyTaking people
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIIIBergamo, ItalyTaking people
- ARNAS G. BrotzuCagliari, ItalyTaking people
- Azienda Unita Sanitaria Locale Di ModenaCarpi, ItalyTaking people
- Azienda Istituti Ospitalieri di CremonaCremona, ItalyTaking people
- Careggi University HospitalFlorence, ItalyTaking people
- Azienda Sanitaria Locale Napoli 2 NordFrattamaggiore, ItalyTaking people
- University of L'AquilaL’Aquila, ItalyTaking people
- Alessandro Manzoni HospitalLecco, ItalyTaking people
- Azienda Socio Sanitaria Territoriale Ovest MilaneseLegnano, ItalyTaking people
- Asst Di MantovaMantova, ItalyTaking people
- Azienda Unita Sanitaria Locale Toscana Nord OvestMassa, ItalyTaking people
- Azienda Ospedaliera Ospedale Niguarda Ca' GrandaMilan, ItalyTaking people
- Azienda Sociosanitaria Territoriale Santi Paolo E CarloMilan, ItalyTaking people
- University Of CagliariMonserrato, ItalyTaking people
- Azienda Ospedaliera di Rilievo Nazionale Antonio CardarelliNaples, ItalyTaking people
- Azienda Ospedaliero Universitaria Maggiore della CaritàNovara, ItalyTaking people
- Azienda Ospedaliera Ospedali Riuniti Villa Sofia - CervelloPalermo, ItalyTaking people
- Azienda Ospedaliera Universitaria Policlinico Paolo GiacconePalermo, ItalyTaking people
- University Hospital Of PerugiaPerugia, ItalyTaking people
- Università di PisaPisa, ItalyTaking people
- San Camillo Forlanini HospitalRome, ItalyTaking people
- University of Rome Tor VergataRome, ItalyTaking people
- Azienda Sanitaria Universitaria Giuliano IsontinaTrieste, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Of Nottingham
- Trial code
- EU 2022-500587-35-01
- Record updated
- 14 September 2026
- Original description
To assess the clinical effectiveness of TXA after ICH and determine whether TXA should be used in clinical practice. Primary objective: To assess the effect of TXA on early death (≤28days)Read full original descriptionShow less
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
To assess the clinical effectiveness of TXA after ICH and determine whether TXA should be used in clinical practice. Primary objective: To assess the effect of TXA on early death (≤28days)